The significant impact of IBD's relapsing and remitting nature on patient well-being, coupled with its malignant potential, has led to the development of a variety of biological drugs such as antitumor necrosis factor alpha (a-TNFα) antibodies [7]. This evidence concerns the gene TNF and inflammatory bowel disease.